Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Porras

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Boletin Medico Del Hospital Infantil De Mexico|December 1, 1993
[Prenatal ultrasonographic diagnosis and early surgical treatment in choledochal cyst]G Porras-Ramírez, M H Hernández-Herrera, M A Soto-Sánchez, et al.
Journal of Clinical Pharmacology|February 8, 2002
Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteersJules I Schwartz, Peggy H Wong, Arturo G Porras, et al.
The European Journal of Neuroscience|March 27, 2001
Neurochemical and electrophysiological evidence that 5-HT4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal, dopaminergic functionG Lucas, V Di Matteo, P De Deurwaerdère, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 1995
Cyclospora cayetanensis infection in patients with and without AIDS: biliary disease as another clinical manifestationJ Sifuentes-Osornio, G Porras-Cortés, R P Bendall, et al.
Gaceta Medica De Mexico|January 1, 1992
[Genetic disorders in sexual differentiation in humans]F Salamanca-Gómez, S H Kofman-Alfaro, S A Cuevas-Covarrubias, et al.
Journal of Clinical Pharmacology|March 6, 2003
Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjectsJules I Schwartz, Saurabh Mukhopadhyay, Arturo G Porras, et al.
Journal of Clinical Pharmacology|October 1, 2003
An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probeKenneth Bachmann, Donald White, Luis Jauregui, et al.
Journal of Clinical Pharmacology|October 5, 2001
Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteersN G Agrawal, A G Porras, C Z Matthews, et al.
Journal of Clinical Pharmacology|January 6, 2001
Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteersJ I Schwartz, M De Smet, P J Larson, et al.
Clinical Pharmacology and Therapeutics|September 1, 1995
Studies of the oral bioavailability of alendronateB J Gertz, S D Holland, W F Kline, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Boletin Medico Del Hospital Infantil De Mexico|December 1, 1993
[Prenatal ultrasonographic diagnosis and early surgical treatment in choledochal cyst]G Porras-Ramírez, M H Hernández-Herrera, M A Soto-Sánchez, et al.
Journal of Clinical Pharmacology|February 8, 2002
Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteersJules I Schwartz, Peggy H Wong, Arturo G Porras, et al.
The European Journal of Neuroscience|March 27, 2001
Neurochemical and electrophysiological evidence that 5-HT4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal, dopaminergic functionG Lucas, V Di Matteo, P De Deurwaerdère, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 1995
Cyclospora cayetanensis infection in patients with and without AIDS: biliary disease as another clinical manifestationJ Sifuentes-Osornio, G Porras-Cortés, R P Bendall, et al.
Gaceta Medica De Mexico|January 1, 1992
[Genetic disorders in sexual differentiation in humans]F Salamanca-Gómez, S H Kofman-Alfaro, S A Cuevas-Covarrubias, et al.
Journal of Clinical Pharmacology|March 6, 2003
Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjectsJules I Schwartz, Saurabh Mukhopadhyay, Arturo G Porras, et al.
Journal of Clinical Pharmacology|October 1, 2003
An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probeKenneth Bachmann, Donald White, Luis Jauregui, et al.
Journal of Clinical Pharmacology|October 5, 2001
Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteersN G Agrawal, A G Porras, C Z Matthews, et al.
Journal of Clinical Pharmacology|January 6, 2001
Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteersJ I Schwartz, M De Smet, P J Larson, et al.
Clinical Pharmacology and Therapeutics|September 1, 1995
Studies of the oral bioavailability of alendronateB J Gertz, S D Holland, W F Kline, et al.
Pageof 8